Statute Details
- Title: Healthcare Services (Human Tissue Banking Service) Regulations 2023
- Act Code: HSA2020-S413-2023
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: Healthcare Services Act 2020
- Enacting Power: Section 57 of the Healthcare Services Act 2020
- Commencement: 26 June 2023
- Status / Version: Current version as at 27 Mar 2026
- Parts: Part 1 (Preliminary), Part 2 (Personnel and Processes), Part 3 (Premises and Equipment), Part 4 (Safety Requirements), Part 5 (Collection, Storage, Distribution and Return of Human Tissue), Part 6 (Miscellaneous)
- Key Provisions (from extract): Definitions (s 2); Application and precedence (s 3); Specified services (s 4); Notification for additional tissue types (s 5); Prohibited service delivery modes (s 6); Consent and donor safeguards (ss 16–18, 28); Quality and governance (ss 7–10); Safety programme and PPE (ss 13–15); Distribution controls and approvals (ss 21–25); Records and continuity (ss 31–33); Outsourcing and pricing transparency (ss 36–37); Offences (s 38)
- Schedules: First Schedule (Specified services); Second Schedule (Infectious diseases)
What Is This Legislation About?
The Healthcare Services (Human Tissue Banking Service) Regulations 2023 (“the Regulations”) set out the detailed regulatory framework for licensing and operating a human tissue banking service in Singapore. In plain terms, they impose rules on how tissue banks must govern their staff and processes, manage premises and equipment, ensure safety, and control the entire lifecycle of human tissue—from donor consent and screening, through collection, processing, storage and distribution, to return and record-keeping.
The Regulations sit alongside the Healthcare Services Act 2020 and the Healthcare Services (General) Regulations 2021. They do not replace the general licensing regime; rather, they add specialised requirements for tissue banking. Where there is inconsistency, the Regulations prevail to the extent the matter relates to a licensee’s human tissue banking service.
Practically, the Regulations are designed to reduce risks to donors and recipients. They address clinical governance, quality management, infection control, traceability, and decision-making authority (including approvals by a Clinical Governance Officer). They also regulate operational models—prohibiting certain delivery modes such as using non-permanent premises, conveyances, or remote provision.
What Are the Key Provisions?
1. Scope, definitions, and precedence. The Regulations apply in addition to the General Regulations and prevail in case of inconsistency, insofar as the matter relates to a licensee. The definitions in section 2 are central to compliance. For example, “donor” includes both living and deceased individuals; “collect” means removing tissue from the donor’s body; and “transplant” includes transferring tissue to the donor’s body or to another individual, whether or not the tissue is processed or manipulated after removal. These definitions matter because many operational duties (consent, screening, distribution restrictions, record-keeping) attach to these concepts.
2. Specified services and expansion to new tissue types. Section 4 ties the Regulations to “specified services” listed in the First Schedule for purposes of section 9A(1) of the Healthcare Services Act 2020. This is a licensing boundary: a tissue bank’s permitted activities are anchored to the specified services. If a licensee intends to handle, process, test, store or distribute a type of human tissue not set out in the First Schedule, section 5 requires written notice to the Director-General at least two months before the licensee starts those activities. This creates a regulatory “gatekeeping” mechanism for scope expansion, allowing the regulator to assess whether additional safeguards are needed.
3. Prohibited service delivery modes. Section 6 is an operational constraint. A licensee must not provide a human tissue banking service using: (a) premises other than permanent premises; (b) a conveyance; or (c) by remote provision. For practitioners, this is significant because it limits how tissue banking can be organised logistically. For example, it discourages “mobile” or “pop-up” tissue handling models and prohibits remote provision as a service delivery mode—likely reflecting the need for controlled environments, validated storage, and direct oversight of safety and quality processes.
4. Governance, personnel competence, and quality management. Part 2 requires a robust internal governance structure. Section 7 focuses on qualifications, skills and competencies of the Clinical Governance Officer. Section 8 addresses appointment of an advising specialist. Section 9 sets general requirements relating to personnel, and section 10 mandates a quality management system. Together, these provisions require more than ad hoc clinical practice: they require a structured system for ensuring that tissue banking activities are performed consistently, safely, and in accordance with regulatory standards. In enforcement terms, these provisions also provide clear benchmarks for what “good governance” looks like—useful when investigating non-compliance or adverse events.
5. Premises, equipment, and safety programme. Part 3 requires permanent premises (section 11) and sets requirements relating to equipment and materials (section 12). Part 4 then requires a safety programme (section 13) and obliges the licensee to ensure personnel comply with it (section 14). Section 15 requires that personal protective equipment must be provided. These provisions collectively address both physical infrastructure and operational safety culture. For lawyers advising tissue banks, they are also relevant to risk assessments, incident investigations, and audit readiness.
6. Donor consent, screening, and communicable disease controls. Part 5 contains the most clinically sensitive duties. Section 16 requires written consent for collection and use of human tissue. Section 17 requires evaluation and screening of donors. Section 18 covers collection of human tissue, while sections 19 and 20 address processing/testing/quarantine and storage. Section 27 requires preventing the spread of communicable disease, and section 28 addresses withdrawal of consent. These provisions reflect a donor-centred approach: consent is not merely a formality, and screening and infection control are integral to the bank’s obligations.
7. Distribution controls and approvals. Distribution is tightly regulated. Section 21 addresses suitability of human tissue for distribution, while section 22 imposes restrictions on distribution. Section 23 requires distribution to be carried out in a safe manner. Critically, section 24 requires approval of distribution by the Clinical Governance Officer, creating a formal decision point and accountability. Section 25 requires provision of information relating to human tissue distributed for transplant—supporting recipient safety and enabling informed clinical use. Section 26 provides for return of human tissue, which is important where tissue cannot proceed to transplant or where regulatory/clinical conditions require retrieval or cessation.
8. Records, traceability, continuity, and outsourcing. Part 6 includes operational and compliance infrastructure. Section 31 requires keeping of records enabling identification of the donor—traceability is essential for safety, audits, and potential follow-up. Section 32 sets general requirements for record-keeping. Section 33 requires continuity of operations, which is particularly relevant for disaster recovery, equipment failure, power outages, and other disruptions that could compromise storage conditions. Section 36 addresses outsourcing, meaning that if a tissue bank relies on external parties for certain functions, it must still meet regulatory obligations (and cannot outsource away accountability). Section 35 requires that tests on persons must be conducted by licensed persons or accredited laboratories, reinforcing quality assurance.
9. Import of processed tissue, abnormal findings, and pricing transparency. Section 29 regulates import of processed human tissue. Section 30 requires notification of abnormal or incidental findings, which links to donor welfare and potentially reproductive or health implications. Section 37 requires price transparency, which may affect how tissue banks structure fees and disclosures to stakeholders.
10. Offences. Section 38 provides for offences. While the extract does not detail the offence provisions, the presence of a dedicated offences section signals that breaches of the Regulations can trigger criminal or other enforcement consequences. For counsel, this underscores the need for compliance systems that can demonstrate adherence to consent, safety, distribution approval, and record-keeping duties.
How Is This Legislation Structured?
The Regulations are organised into six parts. Part 1 (Preliminary) sets out citation and commencement, definitions, application and precedence, the concept of “specified services,” notification for additional tissue types, and prohibited service delivery modes. Part 2 (Requirements relating to personnel and processes) establishes governance roles (including the Clinical Governance Officer), advising specialist appointment, general personnel requirements, and a quality management system. Part 3 (Premises and equipment) focuses on permanent premises and the adequacy of equipment and materials. Part 4 (Safety requirements) requires a safety programme, compliance by personnel, and provision of PPE. Part 5 (Collection, storage, distribution and return of human tissue) contains the core clinical and operational duties, including consent, donor screening, collection, processing/testing/quarantine, storage, suitability and restrictions on distribution, safe distribution and Clinical Governance Officer approval, information provision, return, communicable disease prevention, and withdrawal of consent. Part 6 (Miscellaneous) covers import, notification of abnormal/incidental findings, record-keeping and traceability, continuity of operations, transfer to another human tissue bank, testing requirements, outsourcing, price transparency, and offences. Two schedules support the framework: the First Schedule lists specified services; the Second Schedule lists infectious diseases relevant to screening and safety controls.
Who Does This Legislation Apply To?
The Regulations apply to persons who hold a licence to provide a human tissue banking service (“licensee”). The duties are imposed on the licensee, but they operate through personnel and governance structures—particularly the Clinical Governance Officer and advising specialists—so compliance obligations effectively extend to how the licensee recruits, trains, authorises, and supervises staff.
In addition, the Regulations affect other stakeholders indirectly. For example, distribution approval and information provision requirements shape how transplanting clinicians and transplanting licensees receive tissue. Testing requirements and communicable disease controls also influence how laboratories and external service providers interact with tissue banks, especially where outsourcing is permitted under Part 6.
Why Is This Legislation Important?
Human tissue banking involves high-stakes risks: donor autonomy and welfare, recipient safety, and public health concerns related to infectious diseases. The Regulations translate these risks into enforceable operational requirements. For practitioners, the key value of the Regulations is that they provide a structured compliance map across the entire tissue banking chain—governance, facilities, safety, consent, screening, processing, storage, distribution, traceability, and incident reporting.
From an enforcement perspective, the Regulations create clear accountability points. The Clinical Governance Officer’s approval role for distribution (section 24) is a concrete example: it is not enough to have policies; there must be an authorised decision-maker. Similarly, record-keeping enabling donor identification (section 31) supports traceability and investigation after adverse events or abnormal findings. The prohibited service delivery modes (section 6) also reduce regulatory ambiguity by limiting certain operational models that could undermine safety and oversight.
For legal advisers, the Regulations also matter for licensing strategy and expansion. Section 5’s two-month notice requirement for additional tissue types provides a procedural pathway to broaden services, but it also creates a compliance timeline that must be managed. Finally, the offences provision (section 38) means that non-compliance is not merely administrative; it can carry legal consequences, reinforcing the need for documented quality management systems, validated storage, and controlled distribution processes.
Related Legislation
- Healthcare Services Act 2020 (including section 57 authorising these Regulations and section 9A(1) referenced for specified services)
- Healthcare Services (General) Regulations 2021 (G.N. No. S 1035/2021) — general licensing and compliance framework that these Regulations supplement
- Medical (Therapy, Education and Research) Act 1972 (definition reference for “authorised person” in relation to a deceased donor)
Source Documents
This article provides an overview of the Healthcare Services (Human Tissue Banking Service) Regulations 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.